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Abstract 
Background 
Major depressive disorder (MDD) imposes a considerable disease burden on individuals and 
societies. A large number of randomised controlled trials (RCTs) have shown the efficacy of 
Internet-based guided self-help interventions in reducing symptoms of depression. However, 
study quality varies considerably. The aim of this study is to evaluate the efficacy of a new 
Internet-based guided self-help intervention (GET.ON Mood Enhancer) compared to online-
based psychoeducation in an investigator-blinded RCT. 
Methods/design 
A RCT will be conducted to compare the efficacy of GET.ON Mood Enhancer with an active 
control condition receiving online psychoeducation on depression (OPD). Both treatment 
groups will have full access to treatment as usual. Adults with MDD (n = 128) will be 
recruited and randomised to one of the two conditions. Primary outcome will be observer-
rated depressive symptoms (HRSD-24) by independent assessors blind to treatment 
conditions. Secondary outcomes include changes in self-reported depressive symptom 
severity, anxiety and quality of life. Additionally, potential negative effects of the treatments 
will systematically be evaluated on several dimensions (for example, symptom deteriorations, 
attitudes toward seeking psychological help, relationships and stigmatisation). Assessments 
will take place at baseline, 6 and 12 weeks after randomisation. 
Discussion 
This study evaluates a new Internet-based guided self-help intervention for depression using 
an active control condition (psychoeducation-control) and an independent, blinded outcome 
evaluation. This study will further enhance the evidence for Internet-based guided self-help 
interventions for MDD. 
Trial registration 
German Clinical Trial Registration (DRKS): DRKS00005025 
Keywords 
Guided self-help, Internet-based, Major depressive disorder, Randomised controlled trial, 
Negative effects of psychotherapy, Active control 
Background 
Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders with a 
lifetime prevalence of more than 16 % [1-3]. Moreover, MDD is related to a considerable 
quality of life decrement [4,5], increased mortality rates [6], and substantial economic costs 
[7-9]. Currently, MDD ranks as the fourth disorder with the highest disease burden and is 
projected to be the leading cause of disability in high-income countries by 2030 [10]. 
Although there is ample evidence for the effectiveness of psychotherapy in the treatment of 
depression [11,12], many individuals remain untreated [13]. People who could particularly 
benefit from treatment disregard treatment for several reasons including a lack of knowledge 
of what to do, prohibitive costs, anticipated negative (social) consequences or preference for 
self-help [14]. Moreover, those seeking help hardly receive immediate access to evidence-
based treatment because of long waiting lists for psychotherapeutic treatment [14,15]. 
Limited availability of clinicians, geographical inaccessibility and difficulties to ‘attend 
therapy during usual business hours’ are further barriers. 
Using the Internet to provide guided self-help interventions may help to overcome some of 
the limitations of traditional treatment services. Internet-based guided self-help strategies 
have several advantages over face-to-face approaches. These include: (1) interventions are 
more easily accessible at any time and place; (2) anonymity is assured when patients want to 
avoid stigmatisation; (3) a greater potential for the integration of acquired skills in daily life 
exists because of an emphasis on the participants’ active role in (guided) self-help 
interventions [16]; (4) participants can work at their own pace and go through materials as 
often as they want; (5) travel time and costs for both participants and clinicians are 
eliminated; (6) Internet-based interventions may attract people who do not (want to) make 
use of traditional mental health services [17]; and (7), Internet-based interventions are easily 
scalable, implying that only a small increase of therapeutic resources is required for reaching 
a greater proportion of the eligible population using these interventions. 
Accumulating empirical evidence suggests that Internet-based interventions are well-accepted 
by participants [18] and effective in the treatment of MDD [19], subthreshold depression [20] 
and as maintenance treatment [21]. A systematic review of 19 randomised controlled trials 
(RCTs) evaluating Internet-based interventions for symptoms of depression in 2,996 
individuals [19] found a mean effect size of d = 0.56. Interventions including at least some 
guidance by a clinician were more effective (d = 0.78) than interventions without guidance (d 
= 0.36). Cuijpers (2010) showed that guided self-help interventions for depression (and 
anxiety disorders) could have comparable effects to traditional face-to-face therapy even 
when they are directly compared to each other [22]. 
However, a recent methodological analysis of 75 RCTs of computer- and Internet-based 
interventions for psychiatric disorders [23] criticised the mean methodological quality of 
published trials in the field as rather low. They criticised, for example, that many studies used 
weak control conditions (that is, wait-list control), that most studies relied solely on 
participants’ self-report, and that they failed to include an independent assessment such as 
blind ratings or biological indicators. Moreover, they found that low overall methodological 
quality scores were associated with higher reported effect sizes. In fact, the latest systematic 
review in the field on Internet-based treatments for depression [19] did not include any study 
that used an independent outcome assessment by assessors blind to the treatment condition. 
Moreover, half of the included studies used a wait-list control-only comparison. To the best 
of our knowledge no study on Internet-based treatment for major depression published so far, 
has applied an independent, blinded outcome evaluation. 
Another important issue not adequately addressed to date is the potential negative effects of 
Internet-based treatments for depression. One particularly unfavourable outcome of 
psychotherapy is deterioration of symptoms during treatment. However, RCTs evaluating 
psychological treatments seldom report the number of patients who had deteriorated while 
being treated [24]. Critics of Internet-based treatments have often emphasised that treatment 
might be provided that is less intensive than required to treat severely affected or 
symptomatic individuals [23]. This inadequate treatment allocation may result in less 
treatment expectations for psychotherapy in general and discourage individuals from seeking 
more intensive treatment. Hence, not only is there a pressing need for research on potential 
adverse events of psychotherapy in general [24] but also specifically for Internet-based 
treatments. 
Objective and research questions 
The aim of this study is to evaluate the efficacy of a newly developed guided self-help 
Internet-based intervention (GET.ON Mood Enhancer) compared to an online 
psychoeducation on depression (OPD). 
We expect that observer-rated depressive symptomatology assessed by raters blind to 
treatment conditions will be reduced to a greater extent in the intervention group than in the 
control condition. Moreover, we hypothesise that GET.ON Mood Enhancer is superior in 
terms of self-reported depressive symptoms, wellbeing, quality of life, symptoms of anxiety 
and problem-solving skills compared to the OPD-control condition. Potential negative effects 
with regard to (1) numbers of patients with symptom deteriorations, (2) attitudes towards 
seeking psychological help, and (3) other adverse events will be systematically evaluated. We 
hypothesise that both treatment conditions will not have a negative effect on attitudes towards 
seeking psychological help. 
Methods/design 
Design 
A two-arm RCT will be conducted to compare GET.ON Mood Enhancer with an online 
psychoeducation on depression (OPD) condition. Both treatment arms will have full access to 
treatment as usual. Assessments will take place at baseline (T1), post-treatment (6 weeks, T2) 
and 12-week follow-up (T3; see Figure 1 for a detailed overview of assessments). All 
procedures involved in the study will be consistent with the generally accepted standards of 
ethical practice approved by the University of Marburg ethics committee (No. 2013–08 K). 
The trial is registered in the German clinical trials register under DRKS00005025. 
Figure 1 Study flow. 
Trial status 
By the time of submission, recruitment for the trial was still ongoing. Recruitment started in 
June 2013 and will approximately last until February 2014. 
Participants and procedure 
Inclusion and exclusion criteria 
We will include adults (1) above the age of 18 years (2) with MDD according to DSM-5 
criteria (3) who have Internet access, (4) have sufficient German skills in reading and writing 
(self-report), and (5) are willing to give informed consent. We will exclude subjects (1) with 
a history of manic/hypomanic episodes, (2) with a history of psychotic disorders, (3) 
currently receiving psychotherapy for any kind of mental health problems, (4) showing a 
notable suicidal risk as indicated by a score greater than 1 on BDI Item 9 (‘I feel I would be 
better off dead’), or (5) a change in antidepressive medication dosage/drug within 4 weeks 
before baseline. 
Recruitment 
Participants will be recruited via the GET.ON research website [25] that is announced in 
newspapers, on-air media and related websites. The research website provides information 
about the GET.ON Mood Enhancer training and details about another study evaluating 
GET.ON Mood Enhancer in a sample with subthreshold depression (Trial registration: 
DRKS00004709, [26]). Those participants who do fulfil criteria for a MDD are excluded 
from that study, and instead offered to participate in this trial. 
Assessment of eligibility and randomisation 
People who apply for study participation will receive an information letter with detailed 
information about the study procedures. Full written informed consent will be obtained from 
all participants. They will be informed that they can withdraw from the intervention and/or 
study at any time without any negative consequences. Nevertheless, we will ask those who 
withdraw from the trial treatment to attend all the remaining research appointments or at least 
provide minimal data (primary outcome measure). Applicants who continue to participate in 
the study will be asked to complete online screening questionnaires to assess the severity of 
their depressive symptoms (CES-D >16), whether they are currently receiving any kind of 
treatment for any mental health disease and whether they have a high suicidal risk (BDI Item 
9 > 1). Subjects screened positive and are willing to give informed consent will be scheduled 
for a structured clinical interview (SCID) conducted via the telephone [27]. SCIDs will be 
conducted by trained clinicians. Participants meeting all of the inclusion and none of the 
exclusion criteria, who have completed the baseline assessment, and returned the informed 
consent form will enter the study and will be randomly allocated to study conditions. 
Randomisation will take place at an individual level. The allocation will be performed by an 
independent researcher not otherwise involved in the study using an automated computer-
based random integer generator (randlist). The allocation will be concealed in advance from 
participants, researchers involved in recruitment, and therapists. 
Assessments 
Self-report and observer-rated assessments will take place at baseline, post-intervention and 
12-week follow-up. See Figure 1 for a detailed overview. Self-report data will be collected 
using a secured online-based assessment system (AES, 256-bit encrypted), and observer-
based assessments will be conducted via the telephone by trained interviewers. Observer-
rated assessments will be recorded to examine inter-rater reliability. In case of disagreement, 
the two raters will discuss until a consensus is formed, and the agreed rating will be used for 
analysis. If no agreement is reached after discussion, the assessment will be rated by an 
experienced diagnostic-rater (gold standard), and this rating will be used for analysis. 
Blinding 
The research staff conducting the observer-based rating of depressive symptoms will be 
blinded to the condition the participants are assigned to. Considerable effort is undertaken to 
ensure blindness, including (1) an explanation to the participants why it is important not to 
inform the interviewer about the condition they were assigned to, (2) a written reminder in 
the interview manual for the interviewer to ask the participant not to mention anything about 
their randomisation status, (3) verbal reminders to the patient before the interview, and (4) a 
documentation after the assessment of whether or not the interviewer is still blind to the 
treatment condition. In the event of a blind violation, the interviewer will be changed to the 
following assessment. Participants know about the content of both conditions, but are blinded 
with regard to which intervention is the experimental and which the control condition. 
Intervention 
GET.ON Mood Enhancer 
GET.ON Mood Enhancer is a brief intervention consisting of six lessons with modules 
concerning psychoeducation, behavioral activation (BA), problem solving (PS) and relapse 
prevention. Additionally, participants are offered four modules that can be chosen based on 
individual need and/or preference. Additional modules are directed at sleep problems, 
relaxation techniques and dealing with worrying thoughts (see Table 1 for a session 
overview). Lessons consist of text, exercises and testimonials and also include interactive 
elements such as audio and video clips. A strong focus of the intervention lies on transfer 
tasks (homework assignments) to integrate newly acquired strategies and techniques into 
daily life. In the beginning of each subsequent lesson, participants are invited to reflect on 
their experiences with the newly acquired skills. The training is adaptive as the content is 
tailored to the specific needs of the individual participant by continuously asking participants 
to respond by choosing among various response options. Subsequent content is then tailored 
to the participant’s response. Using responsive web design, participants can follow the 
program on the Internet, a tablet or mobile phone. An integrated read-aloud function allows 
participants to follow narrated lessons. Participants are advised to complete at least one but 
preferably two lessons per week, because a previous meta-regression analysis about the role 
of treatment intensity for treatment outcome in the treatment of depression indicated that 
more frequent therapy sessions might be associated with a better outcome compared to a 
lower frequency of sessions [28]. Consequently, the training lasts about 3 to 6 weeks. We 
decided that we will not include more modules, because (1) a recent meta-analysis [19] found 
that web-based interventions for depression including more than seven modules were less 
effective (d = 0.36) than interventions with seven or less modules (d = 0 .75), and (2) we 
want to lower the threshold for individuals as much as possible. In terms of a stepped-care 
model participants will be encouraged to seek more intensive help in routine mental health 
services, if their progress is not sufficient at the end of the intervention. During the last 
treatment session, they will be provided with information about evidence-based treatments in 
routine mental healthcare and how to obtain access to it. 
Table 1 Overview of GET.ON Mood Enhancer lessons 
Session Topic Content 
1 Psychoeducation • Information about symptoms, causes and types of depression, 
• Role of motivation 
• Introduction of the mood and activity diary 
2 Behavioural 
activation (BA) I 
• Relationship between activities and depression 
• Introduction of daily activity scheduling 
3 Behavioural 
activation (BA) II 
• Reflection on experiences with newly acquired skills and on 
activities/behaviour that might have influenced the mood (from 
now on in every session at the beginning) 
• Coping with difficulties with regard to daily activity scheduling 
• Goal setting for the upcoming days 
• Additional: sleeping problems 
4 Problem-solving 
techniques (PST) I 
• BA: reflection of goal attainment and goal setting for the 
upcoming days 
• PST: distinction between solvable and unsolvable problems 
• PST: introduction of 6-step PST procedure: (1) defining the 
problem, (2) defining the goal, (3) brainstorming about possible 
solutions and choosing the best one, (4) making a plan how to 
implement this solution, (5) putting the solution into practice, 
and (6) evaluating the outcome. 
• PST: choosing one personal problem, filling out steps 1 to 4, 
step 5 as homework 
5 Problem-solving 
techniques (PST) II 
• BA: reflection of goal attainment and goal setting for the 
upcoming days 
• PST: deepening the 6-step procedure: step 6 of the 6-step 
procedure: evaluating outcome; depending on the evaluation: 
coping with difficulties, revising steps 1 to 4 or choosing another 
problem 
• Additional: stop-worrying techniques 
6 Relapse prevention • BA: reflection goal attainment and goal setting for the future 
• PST: step 6 of the 6-step procedure: evaluating outcome 
• Evaluation: summarising gains and learned strategies 
• Developing an individual relapse prevention plan 
• Information about further healthcare services 
The main modules used in GET.ON Mood Enhancer are based on evidence-based face-to-
face manuals that have been found to be effective in the treatment of depression, such as 
behaviour therapy (BT) [29] and problem-solving therapy (PST) [30]. In BT, a strong focus 
rests on daily pleasurable activity scheduling that is integrated in each lesson. The PST 
elements implemented in GET.ON Mood Enhancer have been used in various web-based 
interventions, such as the Dutch web-based ‘Alles onder Controle’ course, which has been 
shown to be effective in reducing depressive symptomatology across several RCTs [31,32]. 
During the training, participants will be supported by an online therapist. Every participant 
will be assigned to one therapist for the duration of the study. The total time a therapist 
spends on a participant will be approximately 2 to 3 hours. Guidance is provided by 
psychotherapists in training supervised by an experienced clinician. Participants will 
communicate with their therapist through the internal messaging function of the system on 
which GET.ON Mood Enhancer is implemented. The guidance is mainly based on the 
supportive-accountability model of providing guidance in Internet-based interventions [33]. 
In the current study, the purpose of the guidance will be to support participants to adhere to 
the treatment modules, and therapists will not teach therapeutic techniques beyond techniques 
used in the treatment modules. All feedback from therapists is stored for supervision and 
adherence checks. 
Psychoeducation on depression condition (OPD) 
The OPD intervention is also Internet-based and is implemented on the same platform as 
GET.ON Mood Enhancer. In the current study, the psychoeducational intervention is based 
on the patient version of the German S3-Guideline/National Disease Management Guideline 
Unipolar Depression [34]. It informs participants about the nature and evidence-based 
treatments of depression including information about symptoms, strategies to overcome 
depression and sources of help. In this study, the psychoeducational intervention requires no 
explicit homework assignments from the participants and provides no therapist support. 
Passive psychoeducational interventions have been shown to be effective in reducing 
depressive symptoms with a pooled standardised effect size of d = 0.26 [35]. 
Treatment as usual 
There will be no restriction on the use of treatment as usual in routine mental health services 
during the study period, such as psychotherapeutic and psychiatric treatment or 
antidepressant medication. However, to control for potential confounding effects, treatment 
utilisation and changes in the dosage of antidepressant medication intake will be monitored 
during the study period. 
Primary and secondary outcomes 
The primary outcome will be observer-rated depression severity. In the secondary analyses, 
we will explore the effects of the treatments on self-reported depression severity, wellbeing, 
anxiety symptoms, quality of life and the number of patients who (1) responded and (2) are in 
remission. Moreover, we will also systematically evaluate potential negative treatment effects 
(that is, symptom deteriorations, negative effects on attitudes towards seeking psychological 
help; other adverse events). 
Measures 
Primary outcome 
The primary outcome will be observer-based rating of depressive symptom severity measured 
by the Hamilton Rating Scale for Depression HRSD24 [36-38]. The HRSD is likely to be the 
most widely used clinician-rated scale for measuring depression in research. The self-report 
measure assesses depressed mood, vegetative and cognitive symptoms of depression, and 
anxiety symptoms. Items are rated on either a 5-point or a 3-point scale, and the total score is 
derived by summing the individual item scores. Higher scores indicate greater symptom 
severity. The HRSD is sensitive to change, inter-rater reliability is 0.90 [36], and the scale 
corresponds well with overall clinical ratings of severity [39,40]. The cutoff points of 10, 19, 
27 and 35 represent the threshold for mild, moderate, severe and very severe depression, 
respectively. 
Secondary outcomes 
Depressive symptoms 
As the secondary outcome, observer-based rating of depression will also be measured using 
the Quick Inventory of Depressive Symptomatology - Clinician-Rating QIDS-CR16 [41,42]. 
The 16-item QIDS-CR16 is a brief clinician-report rating scale developed from the 30-item 
Inventory of Depressive Symptomatology [41-43]. In contrast to the HRSD, it evaluates only 
the nine depression criterion symptom domains (that is, sad mood, concentration, self-
criticism, suicidal ideation, interest/involvement, energy/fatigability, sleep disturbance, 
appetite/weight change and psychomotor agitation/retardation) from the Diagnostic and 
Statistical Manual of Mental Disorders [44] during the prior 7 days. Each item is scored on a 
scale from 0 to 3 points, with higher scores indicating higher symptom severity. This measure 
has shown good psychometric properties, such as strong internal consistency (α = 0.85), 
concurrent validity and sensitivity to symptom change in patients with MDD [42]. The cutoff 
points of 6, 11, 16 and 21 represent the threshold for mild, moderate, severe and very severe 
depression, respectively. 
Self-reported depressive symptoms will be assessed with the Patient Health Questionnaire 
(PHQ-9). This measure has comparable sensitivity and specificity to many other depression 
measures, although it is only half the length. Its internal reliability reaches values between α 
= 0.86 and 0.89 [45,46]. Each item assesses the frequency of a symptom in the last 2 weeks 
on a scale ranging from 0 (‘not at all’) to 3 (‘nearly every day’). In contrast to the primary 
outcome measure HRSD24, the PHQ-9 only assesses frequency of symptoms, not their 
intensity. The total score ranges from 0 to 27, with a higher score indicating more frequent 
symptoms. The cutoff points of 5, 10, 15 and 20 represent the threshold for mild, moderate, 
moderately severe and severe depression, respectively [45,46]. 
Quality of life 
Health-related quality of life will be assessed with the SF-12v1 Health Survey [47]. The SF-
12v1 has 12 items covering eight health domains (physical functioning, physical and 
emotional role functioning, body pain, general health, vitality, social functioning and mental 
health). The SF-12 generates a physical and a mental health summary score. 
Anxiety 
Anxiety will be measured with the anxiety subscale of the Hospital Anxiety and Depression 
Scale HADS-A [48]. The anxiety subscale consists of seven questions and each is scored 
from 0 to 3 with total scores ranging from 0 to 21. A score between 0 and 7 indicates no 
anxiety, between 8 and 10 possible anxiety, and above 11 or 12 a clinical anxiety disorder. 
Psychometric properties are well established [49]. 
Problem-solving skills 
Problem-solving ability (that is, generalised appraisal, beliefs, expectancies and emotional 
responses) will be measured with two subscales of the Social Problem-Solving Inventory-
Revised (SPSI-R). The positive problem orientation (PPO) subscale represents a constructive 
dimension, and the negative problem orientation (NPO) subscale is viewed as a dysfunctional 
dimension. Cronbach’s alphas are α = 0.76 for the PPO dimension and 0.83 for the NPO 
dimension [50]. 
Behavioural activation 
Participants’ activation towards goals or values and pleasant activities and avoidance 
behaviours will be measured with the BADS-Short Form BADS-SF [51]. The BADS-SF 
entails nine items comprising two subscales (activation and avoidance). The items are rated 
on a 7-point Likert-type scale. Higher scores indicate that the participant scores high on the 
area of interest. The internal consistency is α = 0.82 [51]. 
Wellbeing 
Psychological wellbeing will be measured by the World Health Organization’s (WHO) 5 
Wellbeing Index [52]. Participants indicate for each of the five statements, which one is 
closest to how they have been feeling over the prior 2 weeks. Each question is scored from 0 
to 5 with the total score ranging from 0 to 25. Higher scores indicate better wellbeing. 
Problematic alcohol use 
The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item questionnaire designed 
by the WHO to screen for hazardous alcohol intake. It assess three conceptual domains: 
alcohol intake (items 1 to 3), dependence (items 4 to 6) and adverse consequences (items 7 to 
10). Sum-scores can range from 0 to 40, and the generally accepted cutoff point for 
identifying a potential alcohol problem is 8 [53]. 
Treatment credibility/patient expectancy 
Training credibility and participants’ expectancy for improvement will be measured with the 
credibility and expectation questionnaire (CEQ). The CEQ consists of six items which are 
rated on a 9- or sometimes 10-point Likert scale. The psychometric properties of the 
instrument are well established [54]. 
Course evaluation 
In absence of a standardised measure for evaluating course satisfaction in Internet-based 
treatments, user satisfaction will be measured with a self-designed questionnaire based on the 
Client Satisfaction Questionnaire CSQ-8, German Version [55,56]. This self-report measure 
consists of eight items measuring the global client satisfaction with the Internet-based 
training. Previous research indicated a high internal consistency [57]. 
Response and remission 
Participants will be coded as responders when they demonstrate a reliable change according 
to the widely used reliable change index (RCI) [58]. Participants with an RCI of 1.96 or 
above on the primary outcome measure HRSD24 will be considered responders. Remission is 
defined a priori as a non-pathological score of ≤10 on the HRSD24. 
Negative effects 
Negative effects will be measured on (1) symptom deterioration during treatment (2), 
attitudes towards seeking psychological help, and (3) other adverse events. 
(1) Symptom deteriorations 
Patients will be classified as deteriorated when they display a reliable negative change 
(−1.96) in the primary outcome measure HRSD24 according to the reliable change index, 
proposed by Jacobsen & Truax (1991) [58]. 
(2) Negative effects on attitudes towards seeking professional psychological help 
A potential negative influence on attitudes towards seeking mental healthcare service 
utilisation will be measured with the Attitudes Toward Seeking Professional Psychological 
Help Scale-SF ATSPPH-SF [59]. The ATSPPH-SF consists of 10 items that are rated on a 4-
point Likert scale from 0 to 3, yielding a total score ranging from 0 to 30. High scores 
indicate more positive treatment attitudes. The instrument showed good psychometric 
properties [60]. 
Other adverse events 
Other adverse events will be measured with the negative effects of psychotherapy inventory 
(INEP). The INEP is a relatively new measure and was developed for assessing systematic 
and potentially negative effects of psychotherapeutic interventions in different domains. The 
version used in this study consists of 15 items assessing any negative effects participants 
experienced within or after the completion of the Internet-based training on (1) negative 
intrapersonal changes (for example, ‘During treatment or since the end of my therapy, I 
suffered from suicidal thoughts or intentions for the first time ever’), (2) negative effects in 
an intimate relationship (for example, ‘My partner is or has been jealous of my therapist’), (3) 
family/friends (for example, ‘The relationships with my friends has worsened’), (4) perceived 
dependence on the psychotherapist/psychotherapeutic intervention (for example, ‘I feel 
dependent on my therapist’), and (5) stigmatisation (for example, ‘I am anxious that my 
colleagues or friends could find out about my psychotherapy’). The items are rated on a 4-
point Likert scale (0 = no agreement at all; 3 = total agreement). Chronbach’s alpha is α = 
0.85 (Table 2). 
Table 2 Overview of measurements 
  Time of measurement 
Instrument Aim T1 (Baseline) T2 (6 weeks) T3 (12 weeks) 
SCID Diagnostic interview x   
HRSD24 Hamilton Rating Scale for Depression x x x 
QIDS-C16 Quick Inventory for Depressive 
Symptomatology 
x x x 
PHQ-9 Depressive symptomatology x x x 
WHO-5 Wellbeing x x x 
SF-12 Quality of life x x x 
HADS-A Anxiety symptoms x x x 
SPSI-R Problem-solving skills x x x 
BADS-SF Behavioural activation x x x 
CEQ Patient expectancy/treatment credibility x   
ATSPPH-SF Attitudes toward seeking psychological 
help 
x x  
BFI Big Five Inventory x   
INEP Inventory of negative effects in 
psychotherapy 
 x x 
CSQ-8 Clients’ satisfaction with the online 
training 
 x  
AUDIT Alcohol use disorder identification test x   
Other questions Socio-demographics x   
Sample size calculation 
We aim to include 128 participants. This sample will allow us to detect a between-group 
effect size (ES) of d = 0.50 with a power (1-ß) of 80 % and an alpha of 0.05 (calculated using 
PASS 12). The most recent meta-analytic review found a mean ES of d = 0.78 for therapist-
supported web-based interventions for depression [19]. However, most of the included 
studies used a waiting-list control comparison only, and these studies showed a considerably 
larger ES than those studies including a treatment-as-usual condition. Our comparison 
condition will include psychoeducation and full access to treatment as usual and participants 
are encouraged to seek further help. Thus, we expect a somewhat smaller ES of d = 0.50 at 
post-treatment. 
Statistical analyses 
The clinical trial will be conducted in compliance with the Declaration of Helsinki, the 
CONSORT guidelines, GCP and the protocol. Aiming at an intention-to-treat design [61] we 
will include all participants who will be randomly assigned to one of the two conditions. 
Additional per protocol analyses (PPA) will be conducted, including only participants’ 
satisfying protocol treatment (completed at least 4 of 6 modules). Mixed-model analyses of 
variance will be conducted to explore the effects of the treatments on all continuous 
outcomes. Missing data will be handled using multiple imputations (MI). MI is especially 
robust with respect to missing data [62]. Nevertheless, to assess systematic effects of non-
ignorable missing data, pattern mixture analyses for multi-level longitudinal approaches [63] 
will be conducted. To determine if the treatment effect is dependent on missing data, the 
missing-data pattern of each participant will be first coded and then included in a three-way 
interaction (missing pattern × condition × change in depression severity) in the main outcome 
analyses. If no significant interactions between missing-data pattern and treatment outcome 
are found, we will conclude that no missing data bias occurred in the results. For all mixed-
model analyses, Cohen’s d [64] will be calculated by standardising the differences between 
baseline and follow-up scores by the pooled standard deviation of the baseline scores. 
Response and remission rates will be compared across groups with the help of contingency 
tables and χ2 tests. We will also calculate the number needed-to-be-treated (NNT) with 
GET.ON Mood Enhancer to achieve one response and remission, respectively, compared to 
the control group. We will also calculate the number needed-to-harm, which indicates the 
number of participants treated in the experimental condition for one extra person to have a 
symptom deterioration. Because the differential risk of the intervention ideally needs to be set 
into relation with its benefits we will also calculate a benefit-risk ratio [65]. Benefit-risk ratio 
will be calculated by dividing the NNH to achieve one symptom deterioration through the 
NNT to achieve one response. If this benefit-risk ratio is greater than 1, the benefits outweigh 
the risks; if it is 1, the balance between benefit and risks are equal across the groups; if it is 
less than 1, the risks outweigh the benefits (LIT). Benefit-risk ratios will only be calculated 
when differences in risk for symptom deteriorations are statistically significant. 
For other negative effects, we will use independent t-tests for continuous, χ2 for categorical, 
and logistic regression for binary outcomes. In a pre-planned subgroup analysis, we will 
explore negative effects of GET.ON Mood Enhancer on attitudes towards seeking 
psychological help in patients who do not reach the response criteria up to post-assessment (6 
weeks). For all statistical analyses, significance level will be set at P <0.05. All analyses will 
be conducted using SPSS 20. 
Discussion 
MDD is a highly prevalent disorder associated with a considerable loss in quality of life, 
increased mortality rates and substantial economic costs. Several reasons lead to the fact that 
patients remain untreated although they are in need of help. Internet-based guided self-help 
approaches could be an attractive, efficient and cost-effective approach to offer an evidence-
based treatment alternative. Numerous studies have shown the acceptance and efficacy of 
guided self-help interventions in the treatment of depression. However, recent reviews have 
criticised that the methodological quality of studies are low and more high quality studies are 
needed, before such Internet-based therapies are widely disseminated. Moreover, as is also 
the case for face-to-face psychotherapy, hardly anything is empirically known about the 
potential negative effects of Internet-based guided self-help approaches. This study will 
evaluate a new Internet-based intervention for depression (GET.ON Mood Enhancer) 
compared to an online psychoeducation control in an investigator-blinded RCT. Special 
emphasis will be given to systematically evaluate potential negative effects, such as symptom 
deterioration, effects on attitudes towards seeking psychological help and other adverse 
events (that is, perceived intrapersonal negative change, relationships, friendships, family, 
therapeutic malpractice and stigmatisation). 
This study will also have some limitations. First, as in most longitudinal studies we will need 
to deal with the problem of missing values. Although the planned adjustment for missing data 
(Multiple Imputation) is a highly recommended method to handle missing data [62], we will 
nevertheless additionally conduct pattern-mixture analyses [63] to minimise a possible risk 
for bias. Second, ideally the risk for negative effects when providing an Internet-based guided 
self-help intervention to patients with MDD needs to be compared with the risk for negative 
effects in face-to-face psychotherapy. However, a systematic evaluation of potentially 
negative effects of treatment has seldom been conducted for face-to-face psychotherapeutic 
interventions for Major Depression. Therefore, drawing conclusions on the differential risk of 
this guided self-help treatment compared to traditional psychotherapeutic treatment will not 
be possible. Third, the comparison condition does not control for unspecific effects through 
human support. Finally, the study sample will be too small to test for potential moderating 
effects. Thus, which patients are likely to profit from this type of treatment delivery or which 
patients are especially likely to experience negative effects will remain unclear. 
There will also be several strengths of this study, including the strong methodology of a 
randomised controlled design with an active control condition, outcome assessment with 
validated assessments by independent raters blind to treatment condition, a sample defined by 
a standard diagnostic measure, an appropriate statistical analyses plan and handling of 
missing data with state of the art methods. Given these strengths, the results of the study 
should further enhance the evidence-base for Internet-based guided self-help interventions for 
Major Depression. Moreover, a systematic evaluation of potentially negative effects of an 
Internet-based treatment as it is conducted in the present study has to the best of our 
knowledge not been conducted before. This study will therefore provide valuable information 
to the field as the basis for a wide dissemination of such concepts. 
Overall, to overcome the gap between the need for treatment and evidence-based treatment 
availability and treatment utilisation, (cost-) effective low-threshold interventions are needed 
that are accessible for as many people as possible. Internet-based guided self-help 
interventions might be a promising strategy not only as a first step in a stepped-care approach 
but by providing treatments that are more intensive when patients fail to respond. If at some 
point this strategy becomes classified as evidence-based treatment, such approaches could 
provide evidence-based services to patients in areas or countries where psychotherapeutic 
treatment is not readily available [66]. If the proposed trial shows that the investigated 
intervention is not only effective in reducing depressive symptoms but also shows an 
acceptable risk-benefit balance, it would further strengthen the arguments for a wide 
dissemination of Internet-based guided self-help approaches for Major Depression. 
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